SG Americas Securities LLC Has $175,000 Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

SG Americas Securities LLC lifted its holdings in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 33.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 34,562 shares of the company’s stock after acquiring an additional 8,694 shares during the period. SG Americas Securities LLC’s holdings in Wave Life Sciences were worth $175,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of WVE. Wellington Management Group LLP boosted its stake in Wave Life Sciences by 4.3% during the 3rd quarter. Wellington Management Group LLP now owns 264,885 shares of the company’s stock worth $1,523,000 after acquiring an additional 10,830 shares during the last quarter. Newtyn Management LLC boosted its stake in Wave Life Sciences by 2.0% during the 3rd quarter. Newtyn Management LLC now owns 510,000 shares of the company’s stock worth $2,932,000 after acquiring an additional 10,000 shares during the last quarter. Kraematon Investment Advisors Inc. bought a new position in Wave Life Sciences during the 4th quarter worth approximately $237,000. Jump Financial LLC bought a new position in Wave Life Sciences during the 3rd quarter worth approximately $135,000. Finally, Laurion Capital Management LP boosted its stake in Wave Life Sciences by 5.1% during the 3rd quarter. Laurion Capital Management LP now owns 871,500 shares of the company’s stock worth $5,011,000 after acquiring an additional 42,662 shares during the last quarter. Institutional investors and hedge funds own 89.73% of the company’s stock.

Wave Life Sciences Stock Down 3.3 %

Shares of WVE stock opened at $5.80 on Monday. The company’s fifty day simple moving average is $5.32 and its 200-day simple moving average is $5.24. The firm has a market cap of $709.22 million, a PE ratio of -10.55 and a beta of -1.12. Wave Life Sciences Ltd. has a 12 month low of $3.15 and a 12 month high of $7.67.

Wave Life Sciences (NASDAQ:WVE) last issued its earnings results on Wednesday, March 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $29.06 million for the quarter, compared to analyst estimates of $23.30 million. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. On average, equities analysts predict that Wave Life Sciences Ltd. will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Leerink Partnrs raised shares of Wave Life Sciences from a “market perform” rating to an “outperform” rating in a research note on Tuesday, December 19th. HC Wainwright lifted their price target on shares of Wave Life Sciences from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, March 7th. StockNews.com lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 18th. SVB Leerink raised shares of Wave Life Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $5.00 to $12.00 in a research note on Tuesday, December 19th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $17.00 price target on shares of Wave Life Sciences in a research note on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

Insider Buying and Selling

In related news, CFO Kyle Moran sold 15,630 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $6.17, for a total transaction of $96,437.10. Following the transaction, the chief financial officer now directly owns 33,921 shares in the company, valued at $209,292.57. The sale was disclosed in a filing with the SEC, which is available through this link. 31.10% of the stock is owned by corporate insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.